Q BIOMED INC. DL-,001

Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, adding to the already issued patents in Korea, Canada and Japan, which the company says shows tremendous value in the liver cancer market for the asset and which also has  Orphan Drug designation from the US Food and Drug Administration (FDA). The biotech acceleration and commercial stage company said it has exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.» Mehr auf proactiveinvestors.com

Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. The company already holds patents in Korea, Canada and Japan, and Uttroside B previously received Orphan Drug designation from the US Food and Drug Administration.» Mehr auf proactiveinvestors.com

Q BioMed Inc has given itself a big shot in the arm, adding a multi-million dollar asset in the form of an equity stake in long term partner Mannin Research, which has a drug development pipeline poised to be a multi-billion dollar blockbuster franchise for years to come. The company has converted its long-term royalty agreement into a 15% equity stake in private Mannin - a holding, which has a current valuation of C$30 million.» Mehr auf proactiveinvestors.ca